Project Grant K01AR084077
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded a Project Grant of $102,341 to The Leland Stanford Junior University on September 10, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports research into RNA-dependent protein assemblies in epidermal homeostasis, with a project completion date of June 30, 2027. Research will be conducted at Stanford's Palo Alto, California...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded $224,100 in project grant funding to the Regents of the University of California at Riverside on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This three-year project, concluding August 31, 2028, will deliver research investigating epigenetic factors that control epidermal stem cell longevity in adult skin....
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $169,560 Project Grant to The Regents of the University of California, San Francisco (UCSF) effective July 1, 2025, through May 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This mentored career development award funds comprehensive research to elucidate the role of endogenous opioid peptides—specifically enkephalin and...
- Grant Award Summary The Beckman Research Institute of the City of Hope received a $847,746 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) for the five-year period commencing September 1, 2025 through August 31, 2030. The research project, titled "Role of UPR Transducer XBP1 in Pancreatic Beta Cell Survival and Function Under Metabolic Stress,"...
- Federal Project Grant Award Summary The University of Texas Health Science Center at Houston received a $149,264 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective April 5, 2026, with a completion date of December 31, 2028. The research focuses on defining the regulatory role of GA-binding protein (GABP) in pancreatic beta cells, with the...
- Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $1.437 million to the University of Virginia under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) effective May 1, 2026, through April 30, 2029. This Project Grant funds an ancillary research project within the Environmental Determinants of Diabetes in the Young (TEDDY) Study designed to investigate the role of alternative splicing in the initiation and progression...
- Federal Project Grant Award Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded $1,264,088 to the Beckman Research Institute of the City of Hope on July 21, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research on epigenetic regulation of genomic stability in beta-cell homeostasis. The project, which extends through April 30, 2030, aims to elucidate the mechanisms that protect...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $628,968 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective June 20, 2025, with completion targeted for April 30, 2030. The research initiative focuses on defining and treating genetic abnormalities in psoriasis and atopic dermatitis overlap dermatoses...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $250,396 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 5, 2025, with completion anticipated by August 31, 2027. This R21 grant supports research to unravel epigenetic and transcription control mechanisms in skin types from diverse ancestral...
- Award Summary Baylor College of Medicine received a $200,000 Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), with an award date of September 15, 2025, and completion deadline of August 31, 2026. The funded research addresses structural proteome diversity as a determinant of hematopoietic aging through integrated analysis of how protein quality control...
GLUCOSE BINDS RBPS TO REGULATE EPIDERMAL HOMEOSTASIS - GLUCOSE BINDS RBPS TO REGULATE EPIDERMAL HOMEOSTASIS PROJECT SUMMARY/ABSTRACT ONE IN FOUR AMERICANS ARE AFFECTED BY SKIN DISEASE, UNDERSCORING THE IMPORTANCE OF UNDERSTANDING THE MECHANISMS UNDERLYING EPIDERMAL HOMEOSTASIS. OUR LABORATORY RECENTLY FOUND THAT INCREASES IN INTRACELLULAR GLUCOSE CONCENTRATIONS ARE ESSENTIAL FOR DIFFERENTIATION IN THE EPIDERMIS, INDEPENDENT OF GLUCOSE'S METABOLIC FUNCTION. IN THIS CONTEXT, GLUCOSE ACTS TO PROMOTE OR DISSOCIATE SPECIFIC PROTEIN MULTIMERS. RNA-BINDING PROTEINS (RBPS) ARE REQUIRED FOR THE CONTROL OF KERATINOCYTE PROLIFERATION AND DIFFERENTIATION. USING CRISPR-FLOWFISH AND GLUCOSE PULL-DOWN MS TECHNIQUES, WE HAVE IDENTIFIED RBPS AS THE PRIMARY GLUCOSE BINDING PROTEINS THAT CONTROL EPIDERMAL DIFFERENTIATION. AMONG THESE RBPS, DDX21 WAS VALIDATED AS A KEY REGULATOR OF GLUCOSE-MEDIATED RNA AND PROTEIN INTERACTIONS NEEDED TO MAINTAIN NORMAL SKIN HOMEOSTASIS. ADDITIONALLY, WE HAVE DISCOVERED OTHER RBPS THAT BIND GLUCOSE AND ARE ESSENTIAL FOR EPIDERMAL DIFFERENTIATION. THE OBJECTIVE OF THIS K01 APPLICATION IS TO CHARACTERIZE THESE ESSENTIAL GLUCOSE BINDING PROTEINS IN EPIDERMIS. THIS RESEARCH WILL PROVIDE FURTHER INSIGHTS INTO THE NON-METABOLIC ROLES OF GLUCOSE IN EPIDERMAL DIFFERENTIATION AND WILL UNCOVER MECHANISMS OF RBP FUNCTION THAT ARE REGULATED BY DIRECT GLUCOSE BINDING. IN AIM I, WE WILL DEFINE THE MECHANISM FOR GLUCOSE-MEDIATED REGULATION OF DDX50 IN FACILITATING EPIDERMAL DIFFERENTIATION. OUR PRELIMINARY DATA SUPPORTS THE NOTION THAT GLUCOSE PLAYS A CRITICAL ROLE IN REGULATING DDX50 IN THIS CONTEXT. SPECIFICALLY, IN AIM IA, WE WILL ASSESS THE ABILITY OF GLUCOSE TO ENABLE THE FORMATION OF THE DDX50- RNA-STAU1 COMPLEX AND INVESTIGATE HOW THE FUNCTION OF THE COMPLEX IS REGULATED BY GLUCOSE. IN AIM IB, WE WILL EXPLORE ALTERNATIVE MODELS TO UNDERSTAND HOW GLUCOSE REGULATES DDX50'S FUNCTION IN EPIDERMAL DIFFERENTIATION. IN AIM II, WE WILL TEST OUR HYPOTHESIS THAT GLUCOSE PLAYS A ROLE IN DIRECTING NSUN2 AND OTHER RBPS TO CONTROL EPIDERMAL HOMEOSTASIS. OUR PRELIMINARY DATA SUGGESTS THAT GLUCOSE FACILITATES S-ADENOSYL METHIONINE (SAM) BINDING TO NSUN2, WHICH PROMOTES EPIDERMAL DIFFERENTIATION. WE HAVE ALSO IDENTIFIED 51 ADDITIONAL RBPS WITH GLUCOSE-BINDING AFFINITY THAT ARE ALSO ESSENTIAL FOR EPIDERMAL DIFFERENTIATION. IN AIM IIA, WE WILL FOCUS ON TESTING THE SPECIFIC ROLE OF GLUCOSE IN REGULATING NSUN2 IN EPIDERMAL DIFFERENTIATION. IN AIM IIB, WE WILL EVALUATE THE ROLE OF GLUCOSE IN REGULATING ADDITIONAL RBPS INVOLVED IN EPIDERMAL DIFFERENTIATION. MY BACKGROUND IS IN PROTEOMICS, MOLECULAR BIOLOGY, RBP BIOLOGY AND SKIN DIFFERENTIATION. OVER THE COURSE OF THE TRAINING PERIOD AND WITHIN THE ENVIRONMENT OF STANFORD'S DEPARTMENT OF DERMATOLOGY, I PLAN TO ACQUIRE EXPERTISE IN (1) STATISTICS, (2) BIOINFORMATICS, (3) GENOMICS. THIS TRAINING WILL ENABLE ME TO DEVELOP A MORE COMPREHENSIVE UNDERSTANDING OF THE MECHANISMS UNDERLYING GLUCOSE REGULATION IN EPITHELIAL TISSUE, WHICH IS A KEY AREA OF INTEREST IN MY RESEARCH. ULTIMATELY, THIS RESEARCH PLAN WILL PREPARE ME FOR AN INDEPENDENT CAREER AS AN ACADEMIC SCIENTIST FOCUSED ON ELUCIDATING THE MOLECULAR MECHANISMS OF SKIN BIOLOGY.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $112.8k | 6/26/25 | ||
| Not listed | $112.8k | 7/1/24 |